Daewon Clopidogrel Tablets (Clopidogrel Sulfate)

Adult dose

1. For patients with ischemic stroke, myocardial infarction, or peripheral arterial disease, administer clopidogrel 75 mg once daily orally. 2. For patients with acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), begin with 300 mg as a loading dose on the first day of medication, and then continue with 75 mg once daily as a maintenance dose. In this case, aspirin 75 to 325 mg should also be given once daily with this drug.

This drug inhibits the aggregation of platelets in the blood and prevents the formation of clots. This drug may have reduced efficacy in individuals genetically deficient in a specific enzyme (CYP2C19), and alternative treatment options should be considered in such instances. Moreover, concurrent use with drugs that activate CYP2C19 may enhance efficacy and increase bleeding risk, so combination use is not recommended. Persons allergic to this drug or its components, those with bleeding conditions, severe liver impairment, breastfeeding women, and those with genetic issues such as lactose intolerance should not take this medication. Patients at high risk of bleeding, those with impaired liver or kidney function, recent stroke patients, hypertensive patients, elderly individuals, and underweight patients should use this medication with caution, and discontinue 5-7 days prior to any scheduled surgery. As this drug can increase the risk of bleeding, any bleeding symptoms should be immediately discussed with a doctor, and special care should be taken when using with other drugs that also have bleeding risks. This drug can rarely cause serious side effects such as a rapid decrease in white blood cell count; therefore, any fever or signs of infection should be reported to healthcare providers immediately. While taking this medication, side effects such as headache, dizziness, dyspepsia, diarrhea, skin rash may occur, and if symptoms are severe or persistent, a doctor should be consulted. During pregnancy, as there might be an increased risk of bleeding during delivery, it is recommended to discontinue this drug 5-7 days before the expected delivery date. If breastfeeding, as this medication may be passed into breast milk, advice from a doctor should be sought on whether to continue breastfeeding or discontinue the medication. The safety and efficacy of this drug in children have not been established; therefore, it should not be administered to children. Overdose may increase the risk of bleeding, and currently, there are no antidotes available for this drug; thus, in cases of severe bleeding, treatments such as platelet transfusion may be necessary. This drug should be kept out of reach of children and should not be transferred to other containers. Due to the bleeding risk while on this medication, it is essential to inform healthcare providers about its use when starting new medications or undergoing surgery.

Serious side effects

Hives, severe swelling (edema), chest tightness, difficulty breathing, cold sweat, pallor, severe rash with fever, blisters, skin peeling, pain in oral/ocular mucosa, shortness of breath or difficulty breathing, asthma attacks, respiratory abnormalities with cough + fever, jaundice (yellowing of the skin or eyes), profound lethargy, sudden and severe headache, thunderclap headache, seizures, altered consciousness, visual disturbances, paralysis, urination

Mild side effects

• Chest pain
• accidental injury
• influenza-like illness
• pain
• fatigue
• swelling
• hypertension
• headache
• dizziness
• abdominal pain

This medication should be stored in a tightly sealed container to protect it from air or moisture. It is important to maintain a storage temperature between 1 to 30 degrees Celsius (room temperature) to keep the effectiveness and safety of the medication intact.

Appearance

Pink round film-coated tablet

Package unit

Domestic use: 30 tablets/bottle, 300 tablets/bottle; Export use: 100 tablets (10 tablets/PTP×10), 30 tablets (10 tablets/PTP×3)